Evidence map›Paper›PMID 27350105›Full record

ArticleGenetics research2016

FMR1 gene mutations in patients with fragile X syndrome and obligate carriers: 30 years of experience in Chile.

Lorena Santa María, Solange Aliaga, Víctor Faundes, Paulina Morales, Ángela Pugin, Bianca Curotto, Paula Soto, M Ignacia Peña, Isabel Salas, M Angélica Alliende

Open access · bronzeAbstract read
In one paragraph

Article in Genetics research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Lorena Santa MaríaCytogenetics and Molecular Laboratory,Institute of Nutrition and Food Technology (INTA),University of Chile,Santiago,Chile.
Solange AliagaCenter for Diagnosis and Treatment of Fragile X Syndrome Patients (CDTSXF),Institute of Nutrition and Food Technology (INTA),University of Chile,Santiago,Chile.
Víctor FaundesCytogenetics and Molecular Laboratory,Institute of Nutrition and Food Technology (INTA),University of Chile,Santiago,Chile.
Paulina MoralesCytogenetics and Molecular Laboratory,Institute of Nutrition and Food Technology (INTA),University of Chile,Santiago,Chile.
Ángela PuginCenter for Diagnosis and Treatment of Fragile X Syndrome Patients (CDTSXF),Institute of Nutrition and Food Technology (INTA),University of Chile,Santiago,Chile.
Bianca CurottoCytogenetics and Molecular Laboratory,Institute of Nutrition and Food Technology (INTA),University of Chile,Santiago,Chile.
Paula SotoCenter for Diagnosis and Treatment of Fragile X Syndrome Patients (CDTSXF),Institute of Nutrition and Food Technology (INTA),University of Chile,Santiago,Chile.
M Ignacia PeñaCenter for Diagnosis and Treatment of Fragile X Syndrome Patients (CDTSXF),Institute of Nutrition and Food Technology (INTA),University of Chile,Santiago,Chile.
Isabel SalasCenter for Diagnosis and Treatment of Fragile X Syndrome Patients (CDTSXF),Institute of Nutrition and Food Technology (INTA),University of Chile,Santiago,Chile.
M Angélica AlliendeCytogenetics and Molecular Laboratory,Institute of Nutrition and Food Technology (INTA),University of Chile,Santiago,Chile.
University of Chile · CLVictorian Clinical Genetics Services · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fragile X syndrome (FXS) is the most common form of inherited intellectual disability (ID) and co-morbid autism. It is caused by an amplification of the CGG repeat (>200), which is known as the full mutation, within the 5'UTR of the FMR1 gene. Expansions between 55-200 CGG repeats are termed premutation and are associated with a greater risk for fragile X-associated tremor/ataxia syndrome and fragile X-associated premature ovarian insufficiency. Intermediate alleles, also called the grey zone, include approximately 45-54 repeats and are considered borderline. Individuals with less than 45 repeats have a normal FMR1 gene. We report the occurrence of CGG expansions of the FMR1 gene in Chile among patients with ID and families with a known history of FXS. Here, we present a retrospective review conducted on 2321 cases (2202 probands and 119 relatives) referred for FXS diagnosis and cascade screening at the Institute of Nutrition and Food Technology (INTA), University of Chile. Samples were analysed using traditional cytogenetic methods and/or PCR. Southern blot was used to confirm the diagnosis. Overall frequency of FMR1 expansions observed among probands was 194 (8·8%), the average age of diagnosis was 8·8 ± 5·4 years. Of 119 family members studied, 72 (60%) were diagnosed with a CGG expansion. Our results indicated that the prevalence of CGG expansions of the FMR1 gene among probands is relatively higher than other populations. The average age of diagnosis is also higher than reference values. PCR and Southern blot represent a reliable molecular technique in the diagnosis of FXS.

Indexed as

Genetic Predisposition to DiseaseAdolescentAdultBlotting, SouthernChildChild, PreschoolFamilyFemaleFragile X Messenger Ribonucleoprotein 1Fragile X SyndromeGenetic TestingGenotypeHumansInfantMaleMutationFMR1 protein, humanFragile X Messenger Ribonucleoprotein 1

Identifiers

PMID27350105
PMCPMC6865162
OpenAlexW2463125600

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.